-
Neuralstem’s Pipeline Addresses Enormous Unmet Medical Needs
A comprehensive overview of Neuralstem’s NSI-566 cell therapy clinical trials for unmet medical needs – ALS, spinal cord injury, and ischemic stroke – as well as Neuralstem’s novel small molecule drug, NSI-189, nearing the conclusion of its Phase Ib trial in major depressive disorder, expected in the second half of 2013, is the focus of this to-the-minute article.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.